# Olivier Ossipoff

> Olivier Ossipoff is a venture - series unknown investor at Xerys backing Health Care. See 7 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Xerys](https://shizune.co/investors/profile/xerys-funds)
- Location: Paris, France
- Total investments: 7
- Last investment: Feb 2023
- Lead investor: 100%
- Last updated: Aug 2026

Olivier Ossipoff is a venture - series unknown investor at Xerys in Paris focused on Health Care and Biotechnology. Olivier Ossipoff - Chairman @ Xerys

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 29% |
| Biotechnology | 2 | 29% |
| Medical | 1 | 14% |
| Biopharma | 1 | 14% |
| Recycling | 1 | 14% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Venture - Series Unknown | 3 | 43% |
| Series B | 1 | 14% |
| Funding Round | 1 | 14% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| France | 3 | 43% |
| United States | 1 | 14% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Advanced BioDesign | Advanced BioDesign, as an immunotechnology specialist, provides a tailored and high value solution to their research. This new company keeps his main research activity in Oncology, Infectious Diseases and in Neuroscience Fields. One of its major strengths is to follow its customers during the development of their own kits, from the feasibility tothe technology transfer. | $15.6M | Venture - Series Unknown | Feb 02, 2023 |  |
| Biolog-id | Biolog-id is a designer-integrator which has specialized for the last thirty years in electronic identification and mobile data processing. It develops complete solutions for identification and traceability in life science.The mastering of the communication protocols, including those linked to the RFID (Radio Frequency Identification), and thecapacity to develop interface programs, allowing the company to answer to any specific demands is the solution in whichever environment is worked on. About seventy international patents protect the discoveries developed by Biolog-id. | $25M | Venture - Series Unknown | May 05, 2022 |  |
| Skytech | Skytech provides innovative solutions and unique recovery services for plastics for the benefit of manufacturers. Skytech gives plastics a second life. It has developed TRIBLAST, an innovative and patented process for recycling polymers based on triboelectricity. It contributes to the development of the circular economy. | $6.1M | Venture - Series Unknown | Jan 13, 2021 |  |
| Advanced BioDesign | Advanced BioDesign, as an immunotechnology specialist, provides a tailored and high value solution to their research. This new company keeps his main research activity in Oncology, Infectious Diseases and in Neuroscience Fields. One of its major strengths is to follow its customers during the development of their own kits, from the feasibility tothe technology transfer. | $9.8M | Venture - Series Unknown | Feb 25, 2020 |  |
| Biolog-id | Biolog-id is a designer-integrator which has specialized for the last thirty years in electronic identification and mobile data processing. It develops complete solutions for identification and traceability in life science.The mastering of the communication protocols, including those linked to the RFID (Radio Frequency Identification), and thecapacity to develop interface programs, allowing the company to answer to any specific demands is the solution in whichever environment is worked on. About seventy international patents protect the discoveries developed by Biolog-id. | $32.9M |  | Nov 19, 2019 |  |
| Alzprotect | AlzProtect is a biopharmaceutical company developing drug candidates from discovery to clinical trials for the treatment of neurodegenerative diseases including Alzheimer's disease (AD) and orphan tauopathies such as Progressive Supranuclear Palsy (PSP). | $15.4M | Series B | Jan 22, 2018 |  |
| Biolog-id | Biolog-id is a designer-integrator which has specialized for the last thirty years in electronic identification and mobile data processing. It develops complete solutions for identification and traceability in life science.The mastering of the communication protocols, including those linked to the RFID (Radio Frequency Identification), and thecapacity to develop interface programs, allowing the company to answer to any specific demands is the solution in whichever environment is worked on. About seventy international patents protect the discoveries developed by Biolog-id. |  |  |  |  |

7 of 7 investments shown.

## About Xerys

VC Fund · Paris, France

Xery is a portfolio management Company specializing in Venture Capital - Biotech, Medtech, Cleantech, Technology

2 contacts available at Xerys.

| Name | Title | Profile |
| --- | --- | --- |
| Jacques Simonnet | Chairman of the supervisory board | https://shizune.co/investors/profile/jacques-simonnet |
| Olivier Ossipoff | Chairman | https://shizune.co/investors/profile/olivier-ossipoff |

## Similar investors

### Similar stage
- [Bossa Invest](https://shizune.co/investors/profile/bossanova-investimentos) — VC Fund
- [Almi Invest](https://shizune.co/investors/profile/almi-invest) — VC Fund
- [Korea Credit Guarantee Fund](https://shizune.co/investors/profile/korea-credit-guarantee-fund) — VC Fund

## FAQ

### What does Olivier Ossipoff invest in?

Olivier Ossipoff invests primarily in Health Care, Biotechnology and Medical startups, most often at Venture - Series Unknown and Series B stage. Most of the 7 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Olivier Ossipoff last invest?

The most recent investment recorded for Olivier Ossipoff closed in Feb 2023. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co